Andreyev J. Purastat therapy for bleeding radiation proctopathy. World J Gastrointest Endosc 2026; 18(1): 112920 [DOI: 10.4253/wjge.v18.i1.112920]
Corresponding Author of This Article
Jervoise Andreyev, Consultant, Department of Gastroenterology, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, Lincolnshire, United Kingdom. jervoiseandreyev@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Jan 16, 2026; 18(1): 112920 Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.112920
Purastat therapy for bleeding radiation proctopathy
Jervoise Andreyev
Jervoise Andreyev, Department of Gastroenterology, Lincoln County Hospital, Lincoln LN2 5QY, Lincolnshire, United Kingdom
Author contributions: Andreyev J contributed to designed, conducted, analysed and wrote the study.
Conflict-of-interest statement: The author declare that he received Purastat without charge from the manufacturers to treat the patients enrolled in this study but has no other conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jervoise Andreyev, Consultant, Department of Gastroenterology, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, Lincolnshire, United Kingdom. jervoiseandreyev@gmail.com
Received: August 11, 2025 Revised: August 31, 2025 Accepted: December 19, 2025 Published online: January 16, 2026 Processing time: 159 Days and 4 Hours
Abstract
There are limited data as to the effectiveness of Purastat to treat bleeding radiation proctopathy. We present prospectively collected data from a consecutive series of 11 patients with severely symptomatic bleeding radiation proctopathy treated with Purastat. Bleeding reduced after treatment and became very minor or occasional or stopped completely, in all patients after a median of 3 treatments. Two thirds of patents improved with each treatment, one third needed two or more treatments before bleeding reduced. Nuisance scores before treatment were a median 8.5/10 and fell to 0.5/10 at last follow up. The improvement seen was sustained over time.
Core Tip: New data on the effectiveness of Purastat. There are limited data as to the effectiveness of Purastat to treat bleeding radiation proctopathy. Purastat reduced bleeding and improved nuisance scores in 11 patients with severely symptomatic bleeding radiation proctopathy.
